**Core Concept**
The question is testing knowledge of **tardive dyskinesia** treatment, focusing on recently approved pharmacological agents. Tardive dyskinesia is a side effect of long-term use of **neuroleptic drugs**, characterized by involuntary, repetitive body movements.

**Why the Correct Answer is Right**
The correct answer is related to **vesicular monoamine transporter 2 (VMAT2) inhibitors**, which have been shown to decrease the symptoms of tardive dyskinesia. One such drug is **valbenazine**, which has been approved for the treatment of tardive dyskinesia. It works by inhibiting VMAT2, thereby reducing the amount of dopamine released into the synaptic cleft.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not a recently approved drug for tardive dyskinesia.
**Option B:** Incorrect as it does not target the VMAT2 pathway.
**Option C:** Incorrect because it is not specifically approved for tardive dyskinesia.
**Option D:** Incorrect as valbenazine is the correct answer.

**Clinical Pearl / High-Yield Fact**
Valbenazine is a high-yield fact for exams, as it is a recently approved drug for the treatment of tardive dyskinesia, providing a new option for patients with this condition.

**Correct Answer:** D. Valbenazine.